linjc16/ctgov huggingface dataset:
Factor Affecting Childhood Immunization Among Childern.

Study Overview
=================
Brief Summary
-----------------
The aim of study to evaluate the factor affecting underutalization of childhood vaccination immunization among childern below two years of age.

Detailed Description
-----------------
Childhood vaccination has proven to be one of the most effective public health strategies to control and prevent disease.1-5 In an effort to reduce childhood morbidity and mortality, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) issues annual recommendations and guidelines for childhood and adolescent immunizations.2,6-8 However, some parents decline or delay vaccinating their children or follow alternative immunization schedules because of medical, religious, philosophical, or socioeconomic reasons.2,3,4,5,7,9-12Health care provider-based interventions have been suggested to overcome such vaccine noncompliance, including patient counseling; improving access to vaccinations; maximizing patient office visits; offering combination vaccines; and using electronic medical records (EMRs) and practice alerts.2,3,4,7,10,11 Community- and government-based interventions to improve parent and patient adherence include public education and reminder/recall strategies, financial incentives, and providing alternative venues for vaccination.2,7.

Official Title
-----------------
Factor Affecting Childhood Immunization Among Childern Below Two Years

Conditions
-----------------
Child Immunization

Intervention / Treatment
-----------------
* Behavioral: vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All childern in first two years of life who admmitted in hospital or out patient clinic. Exclusion Criteria: : Immunodeficiency (e.g chemotherapy,long term immuno suppressive therapy, hematologic tumor).

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: vaccine|affect vaccination on children|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison between childern below two years who took vaccinations and those who didnot. | The investigators evaluate factors effect of vaccine on the child as scioeconomic status, poverty, chronic disease and residance. | Baseline |
Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma

Study Overview
=================
Brief Summary
-----------------
Colorectal carcinoma is a major health problem. As a malignant tumor, the malignant potential of colorectal carcinoma is based mainly on its ability to metastasis to different sites. Fascin-1 is an actin binding protein which is involved in reconstruction of intracellular actin network, the latter enforces the neoplastic cell to invade surrounding structures.

Detailed Description
-----------------
colorectal carcinoma is an aggressive malignant tumor. It has high incidence of cancer-related morbidity and mortality. the malignant potential of a given neoplasm is based mainly on its ability to invade the surrounding vasculature and reach to distant sites, the latter is called metastasis. in order to metastasize to distant sites, the neoplastic cells must re-arrange the intracellular actin filaments into well formed intracellular assembly which enable the neoplastic cells to reach to distant sites. Fascin-1 is an actin binding protein, it is involved in reconstruction of actin assembly. fortunately, Fascin-1 could be blocked by newly developed medications, blocking of Fascin-1 may limit the metastasis of colorectal carcinoma. in current study the investigators detect Fascin-1 in colorectal carcinoma by immunohistochemical approach, then they correlated different levels of Fascin-1 expression to tumor clinical and pathological criteria as patients' ages, sexes, tumor stages, nodal metastasis, vascular and per-ineural invasions.

Official Title
-----------------
Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma

Conditions
-----------------
Cancer of Colon

Intervention / Treatment
-----------------
* Genetic: Immunohistochemistry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All cases of colorectal carcinoma. Exclusion Criteria: cases diagnosed on basis of lower endoscopic biopsies or local resections without radical colectomy. Patients with preopoerative history of chemo or radiotherapy. Patients with poor clinical data.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Immunohistochemistry|immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1 | correlation of different levels of Fascin-1 expression to patients' ages, sexes, tumor stage, nodal metastasis, vascular and perineural invasion. | September , 2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer Colon, Fascin-1, Actin assembly
DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the impact of itraconzaole on the pharmacokinetics of Dorzagliatin.

Official Title
-----------------
A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics, Pharmadynamics and Safety of HMS5552 Administered Alone or in Combination With Itraconazole in Patients With Type 2 Diabetes Mellitus

Conditions
-----------------
Drug Interaction

Intervention / Treatment
-----------------
* Drug: Dorzagliatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 30-65 Body weight ≥ 50 kg BMI ≥ 19.0 kg/m2 and ≤ 30.0 kg/m2 HbA1c ≥ 7% and ≤ 10.5% FPG ≥ 7.5 mmol/L and ≤ 13.3 mmol/L Exclusion Criteria: T1DM Use of prescription or OTC medications, and herbal within 14 days prior to dosing Blood donation Any surgery or treatment that may impact the ADME of the drug

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequential arm<br>Dorzagliatin administered alone on Day 1; after wash-out, intraconazole was administered from Day 8 to Day 15, with Dorzagliatin administered together on Day 11. | Drug: Dorzagliatin<br>* GKA for T2DM currently under clinical development<br>* Other names: HMS5552;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax | Peak concentration | up to 96 hours | 
| AUClast | Area under the curve | up to 96 hours |
Hyponatremia Due to Poly Ethylene Glycol (PEG)

Study Overview
=================
Brief Summary
-----------------
Colonoscopy is a useful tool used in modern medicine and it is increasingly being employed for both diagnostic and therapeutic purposes. (Polyethelene glycol)PEG is very often used for bowel preparation.There are some cases of hyponatremia reported due to the use of PEG. This study was designed to find frequency of sodium disorders after bowel cleansing by Polyethylene glycol solution for colonoscopies in Dr. Ruth K.M. Pfau, Civil Hospital Karachi.

Detailed Description
-----------------
Colonoscopy is a useful tool used in modern medicine and it is increasingly being employed for both diagnostic and therapeutic purposes. PEG is very often used for bowel preparation. PEG solutions clean the bowel with less water and electrolyte shifts, primarily by causing mechanical effect of large-volume lavage 1. However, there are some cases of hyponatremia reported due to the use of PEG. Life-threatening fluid and electrolyte disturbances are more likely to occur in patients with risk factors, such as old age, use of SSRIs and thiazide diuretics, chronic kidney disease, congestive heart failure or with a history of electrolyte abnormalities 2. Although sporadic case reports of hyponatremia and other electrolyte imbalances after bowel preparation have been reported, but well-designed studies are lacking on this subject. Literature search did not reveal any local studies on this subject. This study was designed to find frequency of sodium disorders after bowel cleansing by Polyethylene glycol solution for colonoscopies in Dr. Ruth K.M. Pfau, Civil Hospital Karachi.

Official Title
-----------------
Frequency of Hyponatremia Caused by Polyethylene Glycol Solution When Used as a Bowel Cleansing Agent for Colonoscopy

Conditions
-----------------
Hyponatremia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of either gender of age between 18-80 years undergoing colonoscopy. Patients should have normal electrolytes before taking solution. Patients should have given informed consent. Patients should have taken solution adequately before procedure. Exclusion Criteria: Patients with chronic kidney disease Patients on diuretics Patients who are hyponatremic on first sample, i.e., before taking bowel cleansing agent. Hypothyroidism -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of hyponatremia caused by polyethelene glycol. | Frequency of hyponatremia caused by polyethelene glycol when used as a bowel cleansing agent for colonoscopy. | 12 hours |
Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease

Study Overview
=================
Brief Summary
-----------------
Our study aims to investigate the benefits of an outpatient pulmonary rehabilitation program in a population of subjects with fibrotic interstitial lung disease. Our hypothesis is that pulmonary rehabilitation will lead to improvements in quality of life, breathlessness, exercise capacity and pulmonary function in this patient population.

Conditions
-----------------
Fibrotic Interstitial Lung Disease

Intervention / Treatment
-----------------
* Behavioral: Pulmonary Rehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Restriction on pulmonary function testing (TLC <80%, FEV1/FVC ratio > predicted or DLCO < 80%) Evidence of fibrosis on high resolution computed tomography of the chest. Fibrosis on surgical lung biopsy if performed Referral for pulmonary rehabilitation Exclusion Criteria: Participation in pulmonary rehabilitation in the past 24 months Inability to complete 6 minute walk test or study questionnaires Limitations other than dyspnea (e.g. arthritis) that affect ability to participate in pulmonary rehabilitation Baseline 6 minute walk distance > 400 meters Planned change in medication treatment for lung disease during the course of pulmonary rehabilitation Ejection fraction known to be < 25% Contraindications to pulmonary rehabilitation (clinically unstable, uncontrolled arrhythmia or hypertension, symptomatic or uncontrolled hypotension with systolic blood pressure of < 95, active angina, unexplained syncope or worsening dizziness, limiting orthopedic or neurological disorders, psychiatric impairment that inhibits cooperation in the program) FEV1/FVC < 65% Unable to provide informed consent
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Pulmonary Rehabilitation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Exercise Improves Executive Function and Dual-task Decrements

Study Overview
=================
Brief Summary
-----------------
A 12-week multicomponent exercise is effective in improving executive function and gait performance in dual-task conditions.

Official Title
-----------------
A Multicomponent Exercise Improves Executive Function and Dual-task Decrements in Gait Among Older Adults

Conditions
-----------------
Older Adults

Intervention / Treatment
-----------------
* Other: Exercise
* Other: Education classes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age more than 65 years old ability to walk outdoor independently without assistive devices Exclusion Criteria: unstable medical conditions interfering with participation in the study diagnosis of dementia, psychosis, neurological disease, and depression unable to receive external information for finishing the neuropsychological tests

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise<br>Multicomponent exercise | Other: Exercise<br>* Multicomponent exercise<br>|
| Placebo Comparator: Education classes<br>Education classes | Other: Education classes<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| spatial and temporal gait parameters | velocity (cm/s), stride time (ms), stride length (cm), stride time variability (%) and stride length variability (%) under single- or two dual-task conditions | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Executive Interview | This test consisted of 25-item rating for executive function on tasks. Scores ranged from 0 to 2 for each item, and higher scores indicated worse performance. | 12 weeks |
Open Repair Versus Branched Endograft Repair for Treatment of Residual Chronic Aortic Arch Dissection During Follow-up After Open Type A Acute Ascending Aorta Replacement: Results From an International Multicenter Study.

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate peri-operative mortality and main post-operative complications (for example cardiovascular, respiratory and renal) in patients treated with frozen elephant trunk techinque.

Official Title
-----------------
Open Repair Versus Branched Endograft Repair for Treatment of Residual Chronic Aortic Arch Dissection During Follow-up After Open Type A Acute Ascending Aorta Replacement: Results From an International Multicenter Study.

Conditions
-----------------
Peri-operative Mortality

Intervention / Treatment
-----------------
* Procedure: Frozen Elephant Trunk Technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with post-dissection arch aneurysm with a maximal aortic diameter >55mm or rapid growth (>10mm/year) Exclusion Criteria: Emergency setting
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Frozen Elephant Trunk Technique|Endovascular technique forTAA repair|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peri-operatory mortality |  | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operatory complications |  | 36 months |
Nutrition as a Determinant of Labor Outcome

Study Overview
=================
Brief Summary
-----------------
This is a randomized, double-blind trial looking at how nutrition intake is associated with labor progress and complications.

Detailed Description
-----------------
Insufficient intake of energy during labor may result in poor labor progress. The study investigates the effect of an energy supplement during labor.

Official Title
-----------------
Nutrition as Determinant of Labor Outcome

Conditions
-----------------
Labor, Obstetric

Intervention / Treatment
-----------------
* Dietary Supplement: Energy-containing soft drink


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women at gestational age > 36 weeks, parity 0 Exclusion Criteria: Gestational age < 36 weeks Signs of fetal pathology: Different or abnormal (pathological) CTG test performed just before start of the test Abnormal Doppler registrations (PI in the arteria umbilicae > 2SD for the gestational age) Established notch in the arteria uterinae or notch bilaterally or PI > 2SD > 24 weeks Diverging in the weight of the fetus > - 22% or diverging in the growth of the fetus - 10% or more, and established structural pathology in the fetus, oligohydramnion (amniotic fluid index < 6) Maternal diseases and pregnancy complications diabetes in pregnancy high blood pressure cardiovascular diseases rheumatic disease epilepsia lung disease, etc. CTG test: cardiotocographic test (a measure of fetal activity) PI: pulsatory index (velocity pattern) SD: standard deviation
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: Energy-containing soft drink|Commercial energy/sports drink|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The course of the labor by women (parity 0) at gestational age > 36 weeks, including: total labor time |  | At time of birth | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stage 1 (cervical opening < 10 cm) and stage 2 (pushing time) |  |  | 
| Use of epidural anesthetics |  |  | 
| Use of contraction-stimulating drugs |  |  | 
| Instrumental delivery |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Labor, instrumental delivery, nutrition, epidural anesthesia, oxytocin
Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome

Study Overview
=================
Brief Summary
-----------------
To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis

Official Title
-----------------
Prognostic Value of Three New Biomarkers of Multiple Sclerosis Compared to Reference Biomarker in Patients With Radiologically Isolated Syndrome

Conditions
-----------------
Multiple Sclerosis, Radiologically Isolated Syndrome

Intervention / Treatment
-----------------
* Other: Analysis of cerebrospinal fluid and serum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Patients have given their free consent for use of their samples in research Patients have at least 2 years of clinical and radiological follow-up data available Exclusion criterion No follow-up of patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Analysis of cerebrospinal fluid and serum|Analysis of biomarkers in patient biological samples|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of tumour necrosis factor receptor in cerebrospinal fluid | ELISA | Baseline | 
| Level of Neurofilament in cerebrospinal fluid | ELISA | Baseline | 
| Level of GFAP in cerebrospinal fluid | ELISA | Baseline | 
| Level of secreted glycoprotein in cerebrospinal fluid | ELISA | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of tumour necrosis factor receptor in serum | ELISA | Baseline | 
| Level of Neurofilament in serum | ELISA | Baseline | 
| Level of GFAP in serum | ELISA | Baseline | 
| Level of secreted glycoprotein in serum | ELISA | Baseline | 
| Comparison of the conversion time according to the threshold value of each biomarker for Radiologically Isolated Syndrome patients | Log-rank test | Baseline | 
| Compare prognostic value of all four markers of the high risk criteria (age below 37, male, myelitis). | Multivariate analysis | Baseline | 
| Biomarker levels in CSF and serum in different patient subpopulations (Radiologically Isolated Syndrome, recurrent remittent MS, symptomatic controls, central nervous system inflammatory disease controls, non-inflammatory disease controls) |  | Baseline |